Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA discusses the possibility of exploiting the biology of the plasma cell for drug therapy in multiple myeloma (MM). Prof Boise mentions the targeting of the cell surface proteins CD28 and CD86 and translating findings into clinical practice.
Recorded at the Myeloma 2016 meeting held in Boston, MA.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.